Cancer Therapeutics Flashcards
Combination therapy for high-grade & intermediate Non-Hodgkin lymphomas (Burkitt lymphoma, lymphoblastic lymphoma, etc)
CHOP = Cyclophosphamide + Doxorubicin (Hydroxydaunorubicin) + Vincristine (Oncovin) + Prednisone
Combination therapy for Hodgkin lymphoma
MOPP = Mechlorethamine + Vincristine (Oncovin) + Procabazine + Prednisone
ABVD = Doxorubicin (Adriamycin) + Bleomycin + Vinblastine + Dacarbazine
Combination therapy for newly-diagnosed pediatric ALL
Vincristine, a corticosteroid (either dexamethasone or prednisone), L-asparaginase, and anthracycline (either doxorubicin or daunorubicin)
**NB: children with ALL are treated according to risk groups, defined by both clinical and laboratory features
Combination therapy for node-positive breast cancers
FEC (CEF) = Fluorouracil + Epirubicin + Cyclophosphamide
FAC (CAF) = Fluorouracil + Doxorubicin (Adriamycin) + Cyclophosphamide
CMF = Cyclophosphamide + Methotrexate + Fluorouracil
Combination therapy for brain cancers (anaplastic astrocytoma, glioblastoma, anaplastic oligodendroglioma)
PCV = Procarbazine + Lomustine (CCNU) + Vincristine
Combination therapy for germ cell cancers (ovarian germ cell cancer, testicular cancer)
PEB = Cisplatin (Platinum) + Etoposide + Bleomycin
Combination therapy for MM
MP = Melphalan + Prednisone
(Old…now M + Bortezomib is standard 1st line therapy).
Avoid melphalan/other alkylation agents if pt is candidate for subsequent stem cell transplantation
VAD = Vincristine + Adriamycin + Dexamethasone
Lenalidomide + dexamethasone = effective 1st line therapy
Combination therapy for metastatic colorectal carcinoma
FOLFOX = Fluorouracil + Leucovorin + Oxaliplatin
FOLFIRI = Folate + FU + Irinotecan
FOLFOX/FOLFIRI + Bevacizumab is now a standard combo
Mechlorethamine
Alkylating agent
Cyclophosphamide
Alkylating agent
Melphalan
Alkylating agent
Thiotepa
Alkylating agent
Dacarbazine
Alkylating agent
Procarbazine
Alkylating agent
Temozolomide
Alkylating agent
Carmustine
Alkylating agent
Lomustine
Alkylating agent
Busulfan
Alkylating agent
Cisplatin
Platinum compound asso w/severe emesis, nephrotoxicity, irreversible neurotoxicity, and hearing loss
Carboplatin
Platinum compound
Oxaliplatin
Platinum compound asso w/peripheral sensory neuropathy, which tends to be reversible
Granisetron
Anti-emetic
Ordansetron
Anti-emetic
Daunorubicin
Anthracycline/Anti-neoplastic ABx
Doxorubicin/Adriamycin
Anthracycline/Anti-neoplastic ABx
Epirubicin
Anthracycline/Anti-neoplastic ABx
Idarubicin
Anthracycline/Anti-neoplastic ABx
Mitomycin
Anti-neoplastic ABx
Dactinomycin
Anti-neoplastic ABx
Bleomycin
Anti-neoplastic ABx
Vinblastine
Antimicrotubule agent; inhibits microtubule assembly/destabilizes microtubules. BM suppression = D-L toxicity. Shortest half-life, fastest clearance rate of the vinca alkaloids
Vincristine
Antimicrotubule agent; inhibits microtubule assembly/destabilizes microtubules. Crosses BBB. Neurotoxicity = D-L toxicity
Vinorelbine
Antimicrotubule agent; inhibits microtubule assembly/destabilizes microtubules. BM suppression = D-L toxicity
Paclitaxel
Antimicrotubule agent; inhibits microtubule disassembly/stabilizes microtubules. D-L toxicity = neutropenia
Docetaxel
Antimicrotubule agent; inhibits microtubule disassembly/stabilizes microtubules. D-L toxicity = neutropenia
Premeds for taxanes (paclitaxel and docetaxel)
Glucocorticoids (dexamethasone) and/or antihistamines (diphenhydramine)
Methotrexate
Folate antagonist. Single agent curative for choriocarcinoma
Pemetrexed
Folate antagonist
Fluorouracil
Pyrimidine antagonist
Capecitabine
Pyrimidine antagonist
Cytarabine
Pyrimidine antagonist
Gemcitabine
Pyrimidine antagonist
Decitabine
Pyrimidine antagonist
Mercaptopurine
Purine antagonist
Fludarabine
Purine antagonist
Cladribine
Purine antagonist
Thioguanine
Purine antagonist
Nelarabine
Purine antagonist
Dasatinib
Kinase inhibitor. Inhibits imatinib-resistant BCR/ABL and other kinases. Approved for imatinib-resistant CML
Erlotinib
Kinase inhibitor; reversibly competes for the binding of ATP to the tyrosine kinase domain of the EGFR tyrosine kinase (like gefitinib). For treatment of locally advanced or metastatic NSCLC refractive to chemotherapy. Most common ADEs are diarrhea and rash.
Gefitinib
Kinase inhibitor; targets EGFR kinase. Originally approved for the treatment of NSCLC refractive to chemotherapy. Indicated only for cancer pts who currently or previously have benefited from treatment.
Imatinib/Gleevec
Kinase inhibitor; selective inhibitor of BCR/ABL, c-kit, and PDGFR tyrosine kinases. Used to treat CML, GIST, and DFSP (dermatofibrosarcoma protuberans). Well tolerated, side effects generally limited to rash, periorbital edema, fluid retention, diarrhea, and myalgia
Lapatinib/Tykerb
Kinase inhibitor; dual inhibitor of HER2 and EGFR protein kinases. For the treatment of patients w/advanced or metastatic breast cancer whose tumors overexpress HER2.
Nilotinib
Kinase inhibitor. Inhibits imatinib-resistant BCR/ABL. Approved for imatinib-resistnat CML.
Sorafenib
Kinase inhibitor. Dual inhibitor of the protein kinase Raf and of VEGFR protein-tyrosine kinases. For use in the treatment of advanced renal cell carcinoma and for unresectable HCC.
Bicalutamide
Anti-androgen
Flutamide
Anti-androgen
Aminoglutethimide
Aromatase inhibitor
Anastrozole
Aromatase inhibitor
Letrozole
Aromatase inhibitor
Tamoxifen
SERM/partial agonist of ER/impairs transcription of estrogen-dependent genes by binding to estrogen response elements (EREs)
Highly effective for postmenopausal women with ER+ breast cancer; also effective in preventing breast cancer in high-risk patients by 50%
A 10x lower affinity than estradiol for the ER
Toremifene
SERM
Goserelin & Leuprolide
GnRH Agonists. Targets testosterone-dependent prostate cancer growth. ADEs = initial symptomatic flair, hot flashes, impotence, gynecomastia
Trastuzumab (Herceptin)
For use as single agent or in combination with paclitaxel for metastatic HER2+ BC.
Recently approved for stomach cancer in combination with chemotherapy in pts with metastatic gastric/gastroesophageal junction adenocarcinoma that expresses HER2.
Cardiomyopathy
Most serious ADE of trastuzumab
ADCC
Mechanism of action of trastuzumab
Cetuximab
Used in combination with irinotecan for EGFR+ metastatic colorectal cancer
Binding prevents Kras activation
Rituximab
Used for the treatment of CD20+ B cell NHL (and CLL)
ADCC, complement
Mechanisms of action of rituximab
Bevacizumab (Avastatin)
Binds VEGF; used in combination with 5-FU for the treatment of metastatic colorectal cancer.
Appears to “normalize” tumor vasculature, which improves drug deliver to the tumor and may improve RT.